BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He K, Cui B, Li G, Wang H, Jin K, Teng L. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther 2012;5:59-65. [PMID: 22570554 DOI: 10.2147/OTT.S29719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res 2021;164:105374. [PMID: 33348026 DOI: 10.1016/j.phrs.2020.105374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vuletic I, Zhou K, Li H, Bai H, Meng X, Zhu S, Ding Y, Li J, Sun H, Ren Q. Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice. Mol Imaging Biol 2017;19:847-56. [PMID: 28315202 DOI: 10.1007/s11307-017-1048-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Ding C, Luo J, Fan X, Li L, Li S, Wen K, Feng J, Wu G. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels. J Exp Clin Cancer Res 2017;36:56. [PMID: 28420432 DOI: 10.1186/s13046-017-0524-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
5 Syed YY, McKeage K. Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs 2015;75:1435-45. [PMID: 26220913 DOI: 10.1007/s40265-015-0444-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
6 Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd FY, Ståhl S, Löfblom J. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep 2014;4:7518. [PMID: 25515662 DOI: 10.1038/srep07518] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
7 Shibeeb O, Vaze A, Gillies M, Gray T. Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab. Case Rep Ophthalmol Med 2014;2014:219792. [PMID: 25349755 DOI: 10.1155/2014/219792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
8 Zhang D, Zhou J, Dong M. Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF. Dig Dis Sci 2014;59:958-67. [PMID: 24370784 DOI: 10.1007/s10620-013-2983-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
9 Meyer N, Akdis CA. Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways. Curr Allergy Asthma Rep 2013;13:1-9. [PMID: 23076420 DOI: 10.1007/s11882-012-0317-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]